Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer (NCT05946213)

🧪 Interventions in This Study

• Biospecimen Collection (PROCEDURE)
• Bone Scan (PROCEDURE)
• Computed Tomography (PROCEDURE)
• External Beam Radiation Therapy (RADIATION)
• Magnetic Resonance Imaging (PROCEDURE)
• Positron Emission Tomography (PROCEDURE)
• Quality-of-Life Assessment (OTHER)
• Questionnaire Administration (OTHER)
• Stereotactic Body Radiation Therapy (RADIATION)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate cancer
2. High-risk disease defined as having at least one or more of the following:
3. cT3a-T3b by digital exam or imaging (American Joint Committee on Cancer \[AJCC\] 8th edition \[Ed.\]) Note: cT4 by imaging or on digital rectal exam is not allowed
4. The patient's prostate specific antigen (PSA) value \> 20 ng/mL prior to starting androgen deprivation therapy (ADT) Note: Patients taking a 5-alpha reductase inhibitor (ex finasteride or dutasteride) are eligible The baseline PSA value should be doubled for PSAs taken while on 5-alpha reductase inhibitors
5. Gleason Score of 8-10
6. Pelvic node positive by conventional imaging with a short axis of at least 1.0 cm
7. Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including MRI or CT scan
8. No definitive clinical or radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI); Negative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is an acceptable substitute
9. Age \>= 18
10. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
11. No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
12. No prior radical prostatectomy

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (413 Sites)

Showing the first 25 of 413 sites.

• University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
• The Kirklin Clinic at Acton Road — Birmingham, Alabama
• Lewis and Faye Manderson Cancer Center — Tuscaloosa, Alabama
• University of Arkansas for Medical Sciences — Little Rock, Arkansas
• Kaiser Permanente-Deer Valley Medical Center — Antioch, California
• Tower Cancer Research Foundation — Beverly Hills, California
• Kaiser Permanente Dublin — Dublin, California
• Kaiser Permanente-Fremont — Fremont, California
• Washington Hospital — Fremont, California
• Fresno Cancer Center — Fresno, California
• Kaiser Permanente Fresno Orchard Plaza — Fresno, California
• Kaiser Permanente-Fresno — Fresno, California
• UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
• Cedars-Sinai Medical Center — Los Angeles, California
• Kaiser Permanente- Modesto MOB II — Modesto, California
• Kaiser Permanente-Modesto — Modesto, California
• Kaiser Permanente Oakland-Broadway — Oakland, California
• Kaiser Permanente-Oakland — Oakland, California
• UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
• Kaiser Permanente-Rancho Cordova Cancer Center — Rancho Cordova, California
• Kaiser Permanente- Marshall Medical Offices — Redwood City, California
• Kaiser Permanente-Richmond — Richmond, California
• Rohnert Park Cancer Center — Rohnert Park, California
• Kaiser Permanente-Roseville — Roseville, California
• The Permanente Medical Group-Roseville Radiation Oncology — Roseville, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Prostate Adenocarcinoma

• Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial — Phoenix, Arizona
• Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer — La Jolla, California
• Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer — Houston, Texas
• Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study — Pittsburgh, Pennsylvania
• Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer — Houston, Texas

Explore by condition: All Prostate Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.